trending Market Intelligence /marketintelligence/en/news-insights/trending/A8iBIKvJWGtvmuqDAzAobA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Altimmune to go public in merger with PharmAthene

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Altimmune to go public in merger with PharmAthene

Altimmune Inc. is going public in a reverse merger transaction with PharmAthene Inc.

The companies plan to merge in an all-stock transaction, with the resulting entity operating under the Altimmune name.

Shareholders of privately held Altimmune will own 58.2% of the combined company, while Altimmune CEO Bill Enright and CFO Elizabeth Czerepak will maintain their positions at the combined business.

The new board will initially comprise three PharmAthene and four Altimmune directors overseeing $20 million in cash and cash commitments as well as four clinical-stage product candidates and one preclinical product.

The merger, which is backed by the boards of both companies, is subject to approval from PharmAthene and Altimmune shareholders.

The merger does not affect PharmAthene's previously announced one-time cash dividend of $2.91 per share as a result of a settlement payment from SIGA Technologies Inc.

Piper Jaffray & Co. advised Altimmune on the transaction.